Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Cardiology/Vascular Diseases
Disease Category: Congestive Heart Failure
Trial Information
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Status: Completed
Protocol Number: CAN0010
Sponsor:
Company Division: Diagnostic
Official Scientific Title: The 'improved management of patients with congestive heart failure in Canada (IMPROVE-CHF CANADA)' study.
Brief Summary: This study will evaluate the use of plasma NT-proBNP measurements to improve the diagnostic accuracy of congestive heart failure (CHF) and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement of plasma NT-proBNP.
Study Phase: N/A
Study Design / Study Details:
- Purpose:
- Allocation: Randomized
- Masking: Double Blind
- Control:
- Assignment: Parallel
- Endpoints:
Study Type:
Interventional
Condition: Congestive Heart Failure
Intervention Type: Diagnostic Test
Intervention Name: ELECSYS®proBNP
Primary Outcome:
Key Secondary Outcomes:
Inclusion Criteria:
- adult patients, >=18 years of age;
- presenting to emergency department with shortness of breath, of suspected cardiac etiology.
Exclusion Criteria:
- dyspnea clearly not due to CHF;
- acute myocardial infarction;
- advanced renal failure.
Gender: Males or Females
Age Limits: Min: 18 Years
Accepts Healthy Volunteers: No
Anticipated Start Date: December, 2004
Trial Registration Date: 11/23/2006
Date Last Updated: 12/08/2006
Link To Trial Results
E-mail: genentechclinicaltrials@druginfo.com
Research Site:
Located In:
Toronto, ON M5G 1X8
Canada
Phone: 888-662-6728 (U.S. Only)
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
